Karyopharm Therapeutics Inc
KPTI
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.71M
Close$
$1.36
287.7% upside
Current Fair Value
287.7% upsideUndervalued by 287.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.71 Million |
|---|---|
| Enterprise Value | $174.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.93 |
| Beta | 1.04 |
| Outstanding Shares | 28,938,000 |
Return
| Return on Equity | 68.07% |
|---|---|
| Return on Assets | -201.89% |
| Return on Invested Capital | 219.39% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | -0.03 |
| Price to Sales | 0.07 |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | 1.19 |
| Enterprise Value to EBIT | -3.47 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.24 |
| Debt to Equity | -0.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.37
Average shareholder expectationRevenue Estimate
$32.19 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$32.93 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3088▼ 9.19% |
|---|---|
| Total Calls | 1,282,400▼ 74.12% |
| Total Puts | 396,000▼ 80.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 73.18%▼ 10.09% |
|---|---|
| Total Invested | $206.96M▲ 102.69% |
| Investors Holding | 112▲ 12.00% |
ESG Score
No data
About Karyopharm Therapeutics Inc
CEO: Michael Kauffman